Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shares of Reed Elsevier NV (ENL - Snapshot Report) have been steadily moving higher since mid-2012, and are now hovering close to their 52-week high. This professional information solutions provider has amassed a year-to-date return of 32%, demonstrating its strong fundamentals. Furthermore, earnings estimates for 2012 and 2013 have shown an upward trend in the last 30 days.
There are several catalysts for this Zacks #1 Rank (Strong Buy) moving forward, including its impressive balance sheet and cash flow generation capability, its diversified business portfolio, acquisitions, divestment activities and its high potential markets.
Nine-Month Results
Reed Elsevier came out with its nine-month results on November 8, 2012. The company witnessed an underlying revenue increase of 4%. Excluding the impact of biennial exhibition cycling, underlying revenue grew 3%. Positive contribution from all five segments set the stage for growth, and the companys underlying revenue and profit upside remain on track.
Looking at segments, the company registered underlying revenue growth of 15% in Reed Exhibitions, 6% in LexisNexis Risk Solutions, 2% in Elsevier, and 1% in LexisNexis Legal & Professional and Reed Business Information each.
To counter the sluggish economic condition and to improve its profitability, Reed Elsevier is now concentrating on those revenue generating avenues that are subscription based and are recurring in nature. The company is also gradually shying away from cyclical advertising-related revenues and print-based products.
Earnings Estimates Edge Upward
The Zacks Consensus Estimate for 2012 rose 1.7% to $2.36 per share in the last 30 days. For 2013, the Zacks Consensus Estimate climbed 4.7% to $2.43 over the same time frame.
Shares Showing Strength
Barring a few occasional pull backs, shares of Reed Elsevier have been trending upward since the beginning of June. It's now hovering close to its 52-week high, reflecting bullish momentum for the rest of 2012. The stock has been consistently trading above its 200-day moving average since August 3. It has also remained above the 50-day moving average since November 23.
Volume averages roughly 35K daily. The year-to-date return for the stock is 32% compared with the S&P 500s return of 10.4%.
Founded in 1903 and based in Amsterdam, the Netherlands, Reed Elsevier is a provider of professional information solutions to science and medical, legal, risk management, and corporate, primarily in North America and Europe. Its 5 divisions are Elsevier, LexisNexis Risk Solutions, LexisNexis Legal & Professional, Reed Exhibitions, and Reed Business Information. Reed Elsevier, which primarily competes with Wolters Kluwer NV (WTKWY), has a market cap of $10.86 billion.
Want More of Our Best Recommendations?
Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential.
Learn More>>
Get the full Snapshot Report on ENL - FREE